Martin G J, Rand J S
Companion Animal Sciences, The University of Queensland, St Lucia, 4072, Australia.
J Feline Med Surg. 2001 Mar;3(1):23-30. doi: 10.1053/jfms.2001.0111.
The aim of this study was to measure the pharmacokinetics and pharmacodynamics of subcutaneously injected 40 IU/ml porcine lente insulin preparation (Caninsulin, Intervet BV, The Netherlands) in diabetic cats. The pharmacological properties of the insulin in poorly controlled or untreated cats were compared with those after several weeks of treatment, to determine if improved diabetic stability altered the pharmacology of this insulin. In addition, the pharmacological properties of intravenously injected 100 IU/ml regular porcine insulin (Actrapid MC, NovoNordisk, Denmark) were measured. Serial plasma samples were collected after subcutaneous injection of porcine lente insulin from 25 diabetic cats in the first week of admission to a 12-month diabetic treatment trial. Samples were also collected after 4 or 8 weeks of treatment, in those cats which had not achieved diabetic remission by this time. At this time, serial plasma samples were also collected from these cats after intravenous injection of porcine regular insulin. Plasma samples were assayed for glucose, anti-insulin antibodies were extracted using a PEG technique, and samples were assayed for insulin using an RIA kit with low sensitivity for endogenous feline insulin, but high sensitivity for exogenous porcine insulin in feline plasma. Caninsulin injected subcutaneously in diabetic cats led to a peak insulin concentration in plasma after 1.7+/-0.1 h, and a nadir of blood glucose after 4.1+/-0.3 h. Insulin and glucose concentrations returned to baseline within 12 h. There was no significant change in the onset or duration of Caninsulin action between the first week of treatment and 5 or 9 weeks of treatment. Actrapid MC injected intravenously had a peak insulin at 0.36+/-0.03 h, and a nadir of blood glucose at 1.9+/-0.3 h. Insulin and glucose returned to baseline within 6 h. It was concluded that Caninsulin injected subcutaneously has suitable pharmacological properties for the twice-daily treatment of diabetes mellitus in cats. In addition, Actrapid MC insulin injected intravenously has suitable pharmacological properties for injection every 4-6 h in diabetic cats.
本研究的目的是测定皮下注射40 IU/ml猪慢胰岛素制剂（甘精胰岛素，英特威国际有限公司，荷兰）在糖尿病猫体内的药代动力学和药效学。将胰岛素在控制不佳或未治疗的猫体内的药理特性与治疗数周后的特性进行比较，以确定糖尿病稳定性的改善是否会改变这种胰岛素的药理作用。此外，还测定了静脉注射100 IU/ml常规猪胰岛素（诺和灵MC，诺和诺德公司，丹麦）的药理特性。在一项为期12个月的糖尿病治疗试验入院第一周，从25只糖尿病猫皮下注射猪慢胰岛素后采集系列血浆样本。对于此时尚未实现糖尿病缓解的猫，在治疗4周或8周后也采集样本。此时，在这些猫静脉注射猪常规胰岛素后也采集系列血浆样本。测定血浆样本中的葡萄糖，使用聚乙二醇技术提取抗胰岛素抗体，并使用对猫内源性胰岛素敏感性低但对猫血浆中外源性猪胰岛素敏感性高的放射免疫分析试剂盒测定样本中的胰岛素。皮下注射到糖尿病猫体内的甘精胰岛素导致血浆中胰岛素浓度在1.7±0.1小时后达到峰值，血糖在4.1±0.3小时后降至最低点。胰岛素和葡萄糖浓度在12小时内恢复到基线水平。治疗第一周与治疗5周或9周之间，甘精胰岛素作用的起效时间或持续时间没有显著变化。静脉注射的诺和灵MC胰岛素在0.36±0.03小时达到胰岛素峰值，血糖在1.9±0.3小时降至最低点。胰岛素和葡萄糖在6小时内恢复到基线水平。得出的结论是，皮下注射甘精胰岛素具有适合每日两次治疗猫糖尿病的药理特性。此外，静脉注射的诺和灵MC胰岛素具有适合糖尿病猫每4 - 6小时注射一次的药理特性。
